[HTML][HTML] Development of a novel quinoline derivative as a P-glycoprotein inhibitor to reverse multidrug resistance in cancer cells

Y Zhou, P Chung, JY Ma, AK Lam, S Law, K Chan… - Biology, 2019 - mdpi.com
Multidrug resistance (MDR) is one of conventional cancer chemotherapy's limitations. Our
group previously synthesized a series of quinoline-based compounds in an attempt to …

[HTML][HTML] Development of a Novel Quinoline Derivative as a P-Glycoprotein Inhibitor to Reverse Multidrug Resistance in Cancer Cells

Y Zhou, P Chung, JY Ma, AK Lam, S Law, K Chan… - Biology, 2019 - ncbi.nlm.nih.gov
Multidrug resistance (MDR) is one of conventional cancer chemotherapy's limitations. Our
group previously synthesized a series of quinoline-based compounds in an attempt to …

[PDF][PDF] Development of a Novel Quinoline Derivative as a P-Glycoprotein Inhibitor to Reverse Multidrug Resistance in Cancer Cells

Y Zhou, P Chung, JY Ma, AK Lam, S Law, K Chan… - pdfs.semanticscholar.org
Multidrug resistance (MDR) is one of conventional cancer chemotherapy's limitations. Our
group previously synthesized a series of quinoline-based compounds in an attempt to …

Development of a Novel Quinoline Derivative as a P-Glycoprotein Inhibitor to Reverse Multidrug Resistance in Cancer Cells.

Y Zhou, PY Chung, JY Ma, AK Lam, S Law, KW Chan… - Biology, 2019 - europepmc.org
Multidrug resistance (MDR) is one of conventional cancer chemotherapy's limitations. Our
group previously synthesized a series of quinoline-based compounds in an attempt to …

Development of a Novel Quinoline Derivative as a P-Glycoprotein Inhibitor to Reverse Multidrug Resistance in Cancer Cells

Y Zhou, PY Chung, JYW Ma, AKY Lam, S Law… - …, 2019 - pubmed.ncbi.nlm.nih.gov
Multidrug resistance (MDR) is one of conventional cancer chemotherapy's limitations. Our
group previously synthesized a series of quinoline-based compounds in an attempt to …

Development of a Novel Quinoline Derivative as a P-Glycoprotein Inhibitor to reverse multidrug resistance in cancer cells

Y Zhou, PY Chung, JYW Ma, AKY Lam, S Law… - Biology, 2019 - hub.hku.hk
Multidrug resistance (MDR) is one of conventional cancer chemotherapy's limitations. Our
group previously synthesized a series of quinoline-based compounds in an attempt to …

Development of a Novel Quinoline Derivative as a P-Glycoprotein Inhibitor to Reverse Multidrug Resistance in Cancer Cells

Y Zhou, P Chung, JY Ma, AK Lam, S Law, K Chan… - 2019 - agris.fao.org
Multidrug resistance (MDR) is one of conventional cancer chemotherapy&# 8217; s
limitations. Our group previously synthesized a series of quinoline-based compounds in an …

Development of a novel quinoline derivative as a P-glycoprotein inhibitor to reverse multidrug resistance in cancer cells

Y Zhou, PY Chung, JYW Ma, AKY Lam, S Law… - Fire safety …, 2019 - ira.lib.polyu.edu.hk
Multidrug resistance (MDR) is one of conventional cancer chemotherapy's limitations. Our
group previously synthesized a series of quinoline-based compounds in an attempt to …

Development of a Novel Quinoline Derivative as a P-Glycoprotein Inhibitor to Reverse Multidrug Resistance in Cancer Cells

Y Zhou, C Po-yee, JY Ma, AK Lam, S Law… - …, 2019 - search.proquest.com
Multidrug resistance (MDR) is one of conventional cancer chemotherapy's limitations. Our
group previously synthesized a series of quinoline-based compounds in an attempt to …

Development of a Novel Quinoline Derivative as a P-Glycoprotein Inhibitor to Reverse Multidrug Resistance in Cancer Cells.

Y Zhou, P Chung, JY Ma, AK Lam, S Law… - Biology (2079 …, 2019 - search.ebscohost.com
Multidrug resistance (MDR) is one of conventional cancer chemotherapy's limitations. Our
group previously synthesized a series of quinoline-based compounds in an attempt to …